L2 Asset Management LLC Invests $5.82 Million in United Therapeutics Corporation $UTHR

L2 Asset Management LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,732 shares of the biotechnology company’s stock, valued at approximately $5,815,000.

A number of other large investors have also added to or reduced their stakes in UTHR. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $31,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on UTHR. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Stock Down 0.0%

Shares of UTHR stock opened at $512.88 on Tuesday. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The stock’s fifty day simple moving average is $532.35 and its 200 day simple moving average is $538.04. The firm has a market capitalization of $22.00 billion, a P/E ratio of 18.35, a P/E/G ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $6.41 earnings per share. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $518.39, for a total value of $4,924,705.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $168,188,006.77. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 434,075 shares of company stock worth $233,942,595 over the last three months. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.